The inaugural session was attended by Dr. Sinaei, Medical Director of Omid Charity Hospital; Dr. Khashabi, Chairman of the Board of Directors of Omid Charity Association; alongside specialists spanning hematology, medical oncology, pathology, radiology, nuclear medicine, pharmacology, anesthesiology and pain management, surgeons from various disciplines, and other allied specialists. The meeting underscored the imperative of harnessing collective clinical knowledge and interdisciplinary experience in the decision-making process for complex oncological cases.
Addressing the assembly, Dr. Sinaei emphasized the critical importance of contemporary therapeutic paradigms, stating: “In certain malignancies, clinical decision-making cannot be confined within the boundaries of a single specialty. Achieving optimal patient outcomes necessitates a comprehensive, multidimensional evaluation conducted collaboratively by specialists from multiple disciplines. Tumor Board sessions provide a structured, scientific forum wherein all dimensions of a patient’s disease — from histopathological and molecular characteristics to imaging findings, staging, comorbidities, and therapeutic options — are rigorously discussed and evaluated, enabling the selection of the most appropriate, personalized treatment pathway for each individual patient.”
He further elaborated on the limitations of conventional referral models: “Under standard practice, patients seeking multiple specialist opinions were compelled to navigate sequential, isolated consultations — a fragmented process that could extend over several weeks, potentially delaying critical treatment initiation. In contrast, Tumor Board sessions convene all relevant specialists simultaneously, facilitating real-time, integrated deliberation on every aspect of the disease in a single, coordinated meeting. This approach not only expedites the decision-making timeline but also ensures that treatment recommendations reflect a true synthesis of multidisciplinary expertise.”
Dr. Sinaei confirmed that these Tumor Board meetings will be convened on a regular monthly basis, adding: “Patient cases requiring collective deliberation and multidisciplinary review will be formally presented at these sessions. Following comprehensive discussion and consensus-building among board members, the necessary therapeutic interventions and management plans will be determined and promptly initiated.”
The session also highlighted the importance of leveraging the scientific capacity of the region’s leading specialists and fostering interdisciplinary collaboration to elevate the quality of oncological care. Participants engaged in substantive discourse on the procedural framework for case presentation, the standardization of clinical data submission, and the mechanisms for ensuring the continuity and institutionalization of Tumor Board meetings.
The establishment of regular Tumor Board sessions at Omid Charity Hospital represents a significant advancement in the institutional commitment to collective medical intelligence and multidisciplinary cancer care. This initiative reflects a paradigm shift toward consensus-driven clinical decision-making, ensuring that treatment plans are informed not by a single perspective, but by the integrated wisdom of diverse specialties — ultimately translating into superior patient outcomes and enhanced quality of oncological care delivery.
